Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: Relationship with cardiovascular risk factors. A case-control study

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Llauradó, Gemma ^a   González Clemente, José Miguel ^a   Maymó Masip, Elsa ^b   Subías, David ^a   Vendrell, Joan ^b   Chacón, Matilde R ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD163 ANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG;

ADULT; AGED; ANTHROPOMETRY; AORTA; AORTIC PULSE WAVE VELOCITY; ARTERIAL STIFFNESS; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CD163 ANTIGEN BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PULSE WAVE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS BLOOD LEVEL; WAIST HIP RATIO;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AORTA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; MIDDLE AGED; PULSE WAVE ANALYSIS; RECEPTORS, CELL SURFACE; RISK FACTORS; TUMOR NECROSIS FACTORS; VASCULAR STIFFNESS;

EID: 84865290761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043919     Document Type: Article

References (32)

1. Libby P, Nathan DM, Abraham K, Brunzell JD, Fradkin JE, et al. (2005) Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation 111: 3489-3493.
2. Sowers JR, Epstein M, Frohlich ED, (2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37: 1053-1059.
3. Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, et al. (2010) Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 31: 1865-1871.
4. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD, (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes-the EURODIAB Prospective Complications Study. Diabetologia 48: 370-378.
5. Wiley SR, Winkles JA, (2003) TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine & growth factor reviews 14: 241-249.
6. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, et al. (2007) Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27: 916-922.
7. Jelic-Ivanovic Z, Bujisic N, Spasic S, Bogavac-Stanojevic N, Spasojevic-Kalimanovska V, et al. (2009) Circulating sTWEAK improves the prediction of coronary artery disease. Clinical biochemistry 42: 1381-1386.
8. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, et al. (2010) Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 30: 1253-1262.
9. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lossner U, et al. (2008) Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 199: 440-444.
10. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, et al. (2007) A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. Journal of immunology 178: 8183-8194.
11. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, et al. (2001) Identification of the haemoglobin scavenger receptor. Nature 409: 198-201.
12. Moller HJ, Peterslund NA, Graversen JH, Moestrup SK, (2002) Identification of the hemoglobin scavenger receptor/CD163 as a natural soluble protein in plasma. Blood 99: 378-380.
13. Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP, (2007) Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis 191: 48-53.
14. Aristoteli LP, Moller HJ, Bailey B, Moestrup SK, Kritharides L, (2006) The monocytic lineage specific soluble CD163 is a plasma marker of coronary atherosclerosis. Atherosclerosis 184: 342-347.
15. Moreno JA, Munoz-Garcia B, Martin-Ventura JL, Madrigal-Matute J, Orbe J, et al. (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207: 103-110.
16. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, et al. (2007) Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 101: 106-110.
17. Llauradó G, Ceperuelo-Mallafré V, Vilardell C, Simó R, Freixenet N, et al. (2012) Arterial stiffness is increased in patients with type 1 diabetes without cardiovascular disease. A potential role of low-grade inflammation. Diabetes Care 35: 1083-1089.
18. Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH, (2011) Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 57: 1511-1522.
19. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, et al. (2006) Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27: 2588-2605.
20. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ, (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49: 626-632.
21. Gonzalez-Clemente JM, Gimenez-Perez G, Richart C, Broch M, Caixas A, et al. (2005) The tumour necrosis factor (TNF)-alpha system is activated in accordance with pulse pressure in normotensive subjects with type 1 diabetes mellitus. Eur J Endocrinol 153: 687-691.
22. Standards of medical care in diabetes-2011 (2011) Diabetes Care. 34Suppl 1: S11-61.
23. Axelsson J, Moller HJ, Witasp A, Qureshi AR, Carrero JJ, et al. (2006) Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD. American journal of kidney diseases: the official journal of the National Kidney Foundation 48: 916-925.
24. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, et al. (1999) TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 274: 8455-8459.
25. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, et al. (2005) TWEAK attenuates the transition from innate to adaptive immunity. Cell 123: 931-944.
26. Carrero JJ, Ortiz A, Qureshi AR, Martin-Ventura JL, Barany P, et al. (2009) Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients. Clinical journal of the American Society of Nephrology: CJASN 4: 110-118.
27. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, et al. (2011) Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis 219: 892-899.
28. Moller HJ, Frikke-Schmidt R, Moestrup SK, Nordestgaard BG, Tybjaerg-Hansen A, (2011) Serum soluble CD163 predicts risk of type 2 diabetes in the general population. Clin Chem 57: 291-297.
29. Koivistoinen T, Virtanen M, Hutri-Kahonen N, Lehtimaki T, Jula A, et al. (2011) Arterial pulse wave velocity in relation to carotid intima-media thickness, brachial flow-mediated dilation and carotid artery distensibility: The Cardiovascular Risk in Young Finns Study and the Health 2000 Survey. Atherosclerosis.
30. Richter B, Rychli K, Hohensinner PJ, Berger R, Mortl D, et al. (2010) Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 213: 545-548.
31. Yilmaz MI, Carrero JJ, Martin-Ventura JL, Sonmez A, Saglam M, et al. (2010) Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation. Clinical journal of the American Society of Nephrology: CJASN 5: 1174-1181.
32. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, et al. (2010) Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 211: 322-326.